Log the date, dose, and injection site in your tracking method of choice
Initial concerns were raised after findings from the cardiovascular outcome trial (CVOT), Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 6 (SUSTAIN 6), revealed a greater risk of DR-related complications, defined as the need for laser therapy, intravitreal injections, development of vitreous hemorrhage, and blindness, in semaglutide users compared to placebo (3.0% vs 1.8%, HR=1.76, P =.02)
offered an improved perspective for the long-term cost-effectiveness of GLP-1 RAs by showcasing benefits in QALYs and reduced lifetime healthcare costs [81]
This oxidative damage can promote the release of autoantigens and disrupt immune tolerance, contributing to the initiation of autoimmune responses against the thyroid